Attralus welcomes Dr. Alex Denner to its Board and announces $116m Series B financing led by Logos Capital

– USA, CA –  Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $116 million Series B financing round led by Logos Capital alongside Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, and founding investor, venBio Partners, also participating.…